Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Opkala, Iheanyi
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease	Terminated	3	236	Europe, US, RoW	Voxelotor, Placebo	Pfizer	Sickle Cell Disease	08/23	11/24
Nonyelu, Charles
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease	Terminated	3	236	Europe, US, RoW	Voxelotor, Placebo	Pfizer	Sickle Cell Disease	08/23	11/24
Okpala, Iheanyi
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises	Terminated	3	72	Europe, US, RoW	Inclacumab, Placebo	Pfizer	Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease	11/23	11/23
RESOLVE, NCT05561140: Resolution of Sickle Cell Leg Ulcers With Voxelotor	Terminated	3	88	RoW	Voxelotor Oral Tablet, Placebo	Pfizer	Sickle Cell Disease, Leg Ulcers	06/24	10/24
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises	Completed	3	243	Europe, US, RoW	Inclacumab, Placebo	Pfizer	Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis	06/24	06/24
Mairami, Amsa
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises	Terminated	3	72	Europe, US, RoW	Inclacumab, Placebo	Pfizer	Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease	11/23	11/23
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises	Completed	3	243	Europe, US, RoW	Inclacumab, Placebo	Pfizer	Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis	06/24	06/24
Iloh, Kenechukwu
No trials found
Unigwe, Uchechukwu
No trials found